Journal
FUTURE ONCOLOGY
Volume 7, Issue 9, Pages 1113-1117Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FON.11.89
Keywords
blemycin, etoposide and cisplatin; chemotherapy; metastatic; MNG; ovarian Sertoli-Leydig cell tumor; SLCT; stem cell transplantation
Categories
Ask authors/readers for more resources
Information regarding treatment for patients with metastatic ovarian Sertoli-Leydig cell tumor (SLCT) has been extremely limited. We report a young woman whose stage IA, poorly differentiated SLCT was initially managed surgically 9 months earlier, and who presented with extensively metastatic SLCT. She had a dramatic response to the combination of bleomycin, etoposide and cisplatin followed by stem cell transplantation and surgery, and has shown no evidence of disease recurrence for 8 months postoperatively. The patient was also found to have sporadic non-toxic multinodular goiter, which has not changed over the treatment course as mentioned. A review of the literature concerning the management of metastatic ovarian SLCT, along with its coexistence with multinodular goiter, is presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available